Putranjivain A from Euphorbia jolkini inhibits proliferation of human breast adenocarcinoma MCF-7 cells via blocking cell cycle progression and inducing apoptosis

Toxicology and Applied Pharmacology

Volumn 213, Issue 1, 2006, Pages 37-45

  Kuo, Po Lin ^a   Cho, Chien Yu ^b   Hsu, Ya Ling ^b   Lin, Ta Chen ^c   Lin, Chun Ching ^b  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Euphorbia jolkini (Euphorbiaceae); Fas ligand; Fas APO 1; p21 WAF1; Putranjivain A

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; EUPHORBIA EXTRACT; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; PROTEIN P21; PUTRANJIVAIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EUPHORBIA; EUPHORBIA JOLKINI; HUMAN; HUMAN CELL; MEDICINAL PLANT; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EUPHORBIA; FAS LIGAND PROTEIN; FEMALE; GALLIC ACID; GLUCOSIDES; HUMANS; MEMBRANE GLYCOPROTEINS; TUMOR NECROSIS FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EUPHORBIA; EUPHORBIA JOLKINI; EUPHORBIACEAE; MINK CELL FOCUS-FORMING VIRUS;

EID: 33646121731     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.08.003     Document Type: Article

References (41)

1. Brinton L., Lacey J., and Devesa S.S. Epidemiology of breast cancer. In: Donegan W.L., and Spratt J.S. (Eds). Cancer of the Breast. 5th ed. (2002), WB Saunders, Philadelphia 111-132
2. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
3. Brown J.M., and Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59 (1999) 1391-1399
4. Chen F.M., Hou M.F., Chang M.Y., Wang J.Y., Hsieh J.S., Ou-Yang F., Huang T.J., and Lin S.R. High frequency of somatic missense mutation of BRCA2 in female breast cancer from Taiwan. Cancer Lett. 220 (2005) 177-184
5. Cheng H.Y., Lin T.C., Yang C.M., Wang K.C., Lin L.T., and Lin C.C. Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage replication of herpes simplex virus type 2 in vitro. Antimicrob. Chemother. 53 (2004) 577-583
6. Chie W.C., Chang S.H., Huang C.S., Tzeng S.J., Chen J.H., Fan B.Y., and Chang K.J. Prognostic factors for the survival of Taiwanese breast cancer patients. J. Formosan Med. Assoc. 101 (2002) 98-103
7. Chopin V., Toillon R.A., Jouy N., and Le Bourhis X. p21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 23 (2004) 21-29
8. Chopin V., Slomianny C., Hondermarck H., and Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res. 298 (2004) 560-573
9. Clifford M.N. Diet-derived phenols in plasma and tissues and their implications for health. Planta Med. 70 (2004) 1103-1114
10. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., and Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76 (1994) 1013-1023
11. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
12. El-Mekkawy S., Meselhy M.R., Kusumoto I.T., Kadota S., Hattori M., and Namba T. Inhibitory effects of Egyptian folk medicines on human immunodeficiency virus (HIV) reverse transcriptase. Chem. Pharm. Bull. 43 (1995) 641-648
13. Falette N., Paperin M.P., Treilleux I., Gratadour A.C., Peloux N., Mignotte H., Tooke N., Lofman E., Inganas M., Bremond A., Ozturk M., and Puisieux A. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 58 (1998) 451-455
14. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 78 (1994) 539-542
15. Fog C.K., Christensen I.J., and Lykkesfeldt A.E. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668. Breast Cancer Res. Treat. 91 (2005) 133-144
16. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., and Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182 (1995) 1223-1230
17. Gartel A.L., and Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65 (2005) 3980-3985
18. Gartel A.L., and Tyner A.L. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 46 (1999) 280-289
19. Gibson S., Tu S., Oyer R., Anderson S.M., and Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274 (1999) 17612-17618
20. Gu Y., Turck C.W., and Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20 K regulatory subunit. Nature 366 (1993) 707-710
21. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
22. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
23. Hsiao W.C., Young K.C., Lin S.L., and Lin P.W. Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res. 6 (2004) R180-R186
24. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., and Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182 (1995) 1777-1783
25. Landowski T.H., Gleason-Guzman M.C., and Dalton W.S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89 (1997) 1854-1861
26. Lee, S.H., 1991. The chemical study of tannins and related compounds of seven Euphorbia plants. PhD Thesis. Kyushu University, Fukuoka-shi, Japan.
27. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., and Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9 (1995) 935-944
28. Mahidhara R.S., Queiroz De Oliveira P.E., Kohout J., Beer D.G., Lin J., Watkins S.C., Robbins P.D., and Hughes S.J. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. J. Surg. Res. 123 (2005) 302-311
29. May P., and May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18 (1999) 7621-7636
30. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer E., and Givol D. Induction of Waf1/CIP1 by a p53-independent pathway. Cancer Res. 54 (1994) 3391-3395
31. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
32. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., and Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
33. Reimer T., Herrnring C., Koczan D., Richter D., Gerber B., Kabelitz D., Friese K., and Thiesen H.J. FasL:Fas ratio-A prognostic factor in breast carcinomas. Cancer Res. 15 (2000) 822-828
34. Semenov D.V., Aronov P.A., Kuligina E.V., Potapenko M.O., and Richter V.A. Oligonucleosome DNA fragmentation of caspase 3 deficient MCF-7 cells in palmitate-induced apoptosis. Nucleosides Nucleotides Nucleic Acids 23 (2004) 831-836
35. Singh B., Bhat T.K., and Singh B. Potential therapeutic applications of some antinutritional plant secondary metabolites. J. Agric. Food Chem. 51 (2003) 5579-5597
36. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76 (1994) 959-962
37. Spencer C.M., Cai Y., Martin R., Gaffney S.H., Goulding P.N., Magnolato D., Lilley T.H., and Haslam E. Polyphenol complexation-Some thoughts and observations. Phytochemistry 27 (1998) 2397-2409
38. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
39. Takahashi N., Li W., Banerjee D., Guan Y., Wada-Takahashi Y., Brennan M.F., Chou T.C., Scotto K.W., and Bertino J.R. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 62 (2002) 6909-6915
40. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
41. Zhou M., Gu L., Yeager A.M., and Findley H.W. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 12 (1998) 1756-1763